NOVI TERAPIJSKI AGENSI U LEČENJU NEUROSARKOIDOZE

Nikola Marić; Aleksa Golubović; Slobodan Belić; Nataša Đurđević; Ivan Milivojević; Miloš Geratović; Mihailo Stjepanović

doi:10.5937/smclk3-41156

Nikola Marić
Aleksa Golubović
Slobodan Belić
Nataša Đurđević
Ivan Milivojević
Miloš Geratović
Mihailo Stjepanović

DOI: https://doi.org/10.5937/smclk3-41156

Ključne reči: sarkoidoza, neurosarkoidoza, kortikosteroidi

Sažetak

Neurosarkoidoza predstavlja relativno čestu ekstrapulmonalnu formu sarkoidoze. Karakterišu je prisustvo različite kliničke slike, mala verovatnoća spontane remisije, značajan uticaj na kvalitet života, kao i potencijalno povećanje mortaliteta. Pored kortikosteroida, u lečenju neurosarkoidoze se primenjuju i drugi lekovi, kao što su metotreksat, azatioprin, mikofenolat mofetil, inhibitori faktora nekroze tumora α (TNF-α), infliksimab i adalimumab. U ovom radu smo, pregledom dostupne literature, pokušali da objedinimo dosadašnja saznanja i novine u lečenju neurosarkoidoze, kako bismo olakšali svakodnevni rad lekarima kliničarima. Dosadašnje studije i dalje daju prednost pulsnim dozama kortikosteroida, dok je druga terapija pokazala prednost samo u pojedinim slučajevima. Ipak, treba napomenuti da su potrebna dodatna istraživanja, kako bi se uspešno razvila individualna terapija.

Reference

1. Gerke AK, Judson MA, Cozier YC, Culver DA, Koth LL. Disease Burden and Variability in Sarcoidosis. Ann Am Thorac Soc. 2017 Dec;14(Supplement_6):S421-S428. doi: 10.1513/AnnalsATS.201707-564OT.

2. Joubert B, Chapelon-Abric C, Biard L, Saadoun D, Demeret S, Dormont D, et al. Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. JAMA Neurol. 2017 Nov 1;74(11):1336-1344. doi: 10.1001/jamaneurol.2017.2492.

3. Fritz D, Voortman M, van de Beek D, Drent M, Brouwer MC. Many faces of neurosarcoidosis: from chronic meningitis to myelopathy. Curr Opin Pulm Med. 2017 Sep;23(5):439-446. doi: 10.1097/MCP.0000000000000401.

4. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999 Sep;16(2):149-73.

5. Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al.; Organ Assessment Instrument Investigators TW. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):19-27.

6. James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol. 2018 Jul;11(7):677-687. doi: 10.1080/17512433.2018.1486706.

7. Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, Brieva L, et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler. 2014 May;20(6):717-25. doi: 10.1177/1352458513508835.

8. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997 Sep 8;157(16):1864-8.

9. Cremers JP, Drent M, Bast A, Shigemitsu H, Baughman RP, Valeyre D, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013 Sep;19(5):545-61. doi: 10.1097/MCP.0b013e3283642a7a.

10. Bitoun S, Bouvry D, Borie R, Mahevas M, Sacre K, Haroche J, et al. Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016 Dec 13;87(24):2517-2521. doi: 10.1212/WNL.0000000000003431.

11. Cohen Aubart F, Bouvry D, Galanaud D, Dehais C, Mathey G, Psimaras D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017 May;264(5):891-897. doi: 10.1007/s00415-017-8444-9.

12. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, et al. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644.

13. Fritz D, Timmermans WMC, van Laar JAM, van Hagen PM, Siepman TAM, van de Beek D, et al. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 27;7(5):e847. doi: 10.1212/NXI.0000000000000847.

14. Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 15;32(4):280-3.

15. Merinopoulos D, Hayes F, Gallagher DA, Dasgupta B. A case report of neurosarcoidosis successfully treated with an infliximab biosimilar after a relapse while on dual therapy. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):356-357.

16. Earle B, Wolf DS, Ramsay ES. Novel Use of Rituximab in Treatment of Refractory Neurosarcoidosis in an 11-Year-Old Girl. J Clin Rheumatol. 2019 Sep;25(6):e101-e103. doi: 10.1097/RHU.0000000000000900. PMID: 30247223.

17. Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018 Oct 26;11:1756286418805732. doi: 10.1177/1756286418805732.

18. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010 Aug 10;75(6):568-70. doi: 10.1212/WNL.0b013e3181ec7ff9.

19. Jovanović D, Grujičić D, Stjepanović M, Popević S, Kontić M, Vučinić Mihailović V. UNUSUAL CLINICAL COURSE OF NEUROSARCOIDOSIS MANIFESTED WITH ACUTE HYDROCEPHALUS. Acta Clin Croat. 2021 Mar;60(1):131-135. doi: 10.20471/acc.2021.60.01.19.

20. Menninger MD, Amdur RJ, Marcus RB Jr. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol. 2003 Aug;26(4):e115-8. doi: 10.1097/01.COC.0000077933.69101.5D.

21. Malmgren K, Lycke J, Engman E, Hedström A, Jönsson L, Rydenhag B, et al. Successful epilepsy surgery in a patient with neurosarcoidosis. Epilepsia. 2010 Jun;51(6):1101-3. doi: 10.1111/j.1528-1167.2010.02580.x.

22. Langrand C, Bihan H, Raverot G, Varron L, Androdias G, Borson-Chazot F, et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM. 2012 Oct;105(10):981-95. doi: 10.1093/qjmed/hcs121.

23. Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol. 2005 Apr;152(4):501-13. doi: 10.1530/eje.1.01886.

24. Sukumaran A. Panhypopituitarism from neurosarcoidosis in an adolescent: case report and literature review. J Pediatr Endocrinol Metab. 2019 Sep 25;32(9):1039-1042. doi: 10.1515/jpem-2019-0110.

25. Jawadi MH, Hanson TJ, Schemmel JE, Beck P, Katz FH. Hypothalamic sarcoidosis and hypopituitarism. Horm Res. 1980;12(1):1-9. doi: 10.1159/000179099.

26. Gen S, Ogawa A, Kanai K, Nobe K, Ikeda N, Mochizuki A, et al. A Case of Neurosarcoidosis-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone Diagnosed with Neuroendoscopy. Case Rep Med. 2018 Aug 6;2018:9496149. doi: 10.1155/2018/9496149.

27. Alam T, Thomas S. Diabetes insipidus secondary to sarcoidosis presenting with caseating granuloma. BMJ Case Rep. 2011 Mar 3;2011:bcr0120113702. doi: 10.1136/bcr.01.2011.3702.

28. Sanghi V, Kapoor A. Unusual Presentation of Central Diabetes Insipidus in a Patient With Neurosarcoidosis. J Investig Med High Impact Case Rep. 2016 Sep 9;4(3):2324709616667511. doi: 10.1177/2324709616667511.

29. Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013 Nov 8;19(1):334-45. doi: 10.2119/molmed.2013.00122.

30. Voortman M, Hendriks CMR, Elfferich MDP, Bonella F, Møller J, De Vries J, et al. The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung. 2019 Apr;197(2):155-161. doi: 10.1007/s00408-019-00206-7.

31. Wilsher ML. Psychological stress in sarcoidosis. Curr Opin Pulm Med. 2012 Sep;18(5):524-7. doi: 10.1097/MCP.0b013e3283547092.

32. Beste C, Kneiphof J, Woitalla D. Effects of fatigue on cognitive control in neurosarcoidosis. Eur Neuropsychopharmacol. 2015 Apr;25(4):522-30. doi: 10.1016/j.euroneuro.2015.01.012.

33. Górski W, Piotrowski WJ. Fatigue syndrome in sarcoidosis. Pneumonol Alergol Pol. 2016;84(4):244-50. doi: 10.5603/PiAP.2016.0030.

34. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003 Aug 1;168(3):323-9. doi: 10.1164/rccm.200211-1343OC.

35. Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA, et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax. 2013 Jan;68(1):57-65. doi: 10.1136/thoraxjnl-2012-201962.